Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

Rhea-AI Summary

Senti Biosciences (Nasdaq: SNTI) will present clinical and translational data for SENTI-202 at the 11th Annual Innate Killer Conference, March 24–25, 2026 in San Diego. Presentations cover Phase I safety and preliminary anti-leukemic activity, correlative analyses supporting the logic-gated mechanism, and a biomarker workshop.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – SNTI

-2.17%

1 alert

-2.17% News Effect

-$525K Valuation Impact

$23.66M Market Cap

0.0x Rel. Volume

On the day this news was published, SNTI declined 2.17%, reflecting a moderate negative market reaction. This price movement removed approximately $525K from the company's valuation, bringing the market cap to $23.66M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores continued emphasis on SENTI‑202, with Phase I clinical and translation...

Analysis

This announcement underscores continued emphasis on SENTI‑202, with Phase I clinical and translational data being showcased at the Innate Killer Conference on March 24–25, 2026. It builds on earlier milestones, including completion of Phase 1 enrollment and prior ASH data. Investors evaluating this news alongside regulatory filings may focus on the company’s cash position, past going‑concern language, and upcoming clinical milestones to gauge how SENTI‑202 progress interacts with financing needs and overall execution risk.

Key Figures

Conference edition: 11th Annual Conference dates: March 24–25, 2026 Trial phase: Phase I

3 metrics

Conference edition 11th Annual Innate Killer Conference

Conference dates March 24–25, 2026 Innate Killer Conference in San Diego

Trial phase Phase I Ongoing SENTI-202 clinical trial in R/R AML

Historical Context

5 past events · Latest: Mar 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 03	Conference presentation	Neutral	+2.1%	CEO presentation at Leerink Partners 2026 Global Healthcare Conference.
Feb 24	Conference presentation	Neutral	+7.1%	CEO presentation at TD Cowen 46th Annual Health Care Conference.
Feb 20	Industry event participation	Neutral	-3.4%	Participation in Cell & Gene Live event on Gene Circuit and SENTI‑202.
Feb 11	Clinical trial update	Positive	-1.9%	Completion of Phase 1 enrollment for SENTI‑202 in R/R AML.
Feb 03	Conference selection	Neutral	-3.0%	Selection for on-stage presentation at Healthcare Conference Taipei 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow has been dominated by conference and event presentations, with mixed price reactions and one notable divergence on positive clinical progress.

Recent Company History

This announcement continues a pattern of Senti Biosciences highlighting its Gene Circuit and SENTI‑202 programs at conferences and events. In February–March 2026, the company presented at multiple healthcare conferences and a Cell & Gene Live event, while in February 2026 it reported completion of Phase 1 enrollment for SENTI‑202 with prior positive ASH 2025 data. Today’s Innate Killer Conference presentations build on that clinical narrative, adding clinical and translational details for SENTI‑202 within an already event-heavy communication cadence.

Key Terms

car nk cell therapy, cd33, flt3, relapsed/refractory acute myeloid leukemia, +3 more

7 terms

car nk cell therapy medical

"a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed"

CAR NK cell therapy uses natural killer (NK) immune cells that have been genetically modified to carry a chimeric antigen receptor (CAR) so they more reliably find and destroy specific cancer cells. Think of it as giving native immune cells a GPS and clearer instructions to hunt tumors. Investors watch this approach because clinical success, manufacturing scalability, safety profile and regulatory approval determine commercial potential, costs and competitive advantage in oncology treatments.

cd33 medical

"designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing"

CD33 is a protein that sits on the surface of certain white blood cells and is commonly present on many acute myeloid leukemia cells; think of it as a visible flag on those cells that helps identify them. It matters to investors because CD33 is a common diagnostic marker and a therapeutic target — drugs or tests that successfully bind or block this “flag” can change treatment outcomes, drive clinical trial value, and influence regulatory approvals and commercial prospects.

flt3 medical

"designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing"

FLT3 is a gene that makes a protein acting like a growth switch for blood-forming stem cells; when that switch is faulty or overactive it can drive certain blood cancers, most notably acute myeloid leukemia. Investors care because drugs that target FLT3 mutations can become important therapies, influencing clinical trial outcomes, regulatory approvals and the future revenues and valuations of biotech companies—think of it as a key control knob whose position can determine a treatment’s market value.

relapsed/refractory acute myeloid leukemia medical

"healthy cells in adults with relapsed/refractory acute myeloid leukemia (AML)."

A form of acute myeloid leukemia (AML) that either returns after an initial response to treatment (relapsed) or fails to improve or continues progressing despite therapy (refractory). For investors, this describes a high unmet medical need and a patient group often targeted by new drugs, clinical trials and regulatory priority pathways, so developments here can meaningfully affect a company’s trial success prospects, market size and potential revenue.

biomarker medical

"Harnessing Biomarker Discovery & Translational Tools to Accelerate NK Therapy"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

translational medical

"biomarker discovery & translational tools to accelerate NK therapy clinical success"

Translational describes the process of turning basic scientific discoveries into practical medical tests, treatments or products that can be used with patients. For investors it signals how close a technology is to real-world use and potential revenue — like converting a prototype into a factory-made product — so strong translational progress can reduce technical risk and increase the chances of commercial returns.

mechanism of action medical

"consistent with clinical activity & unique logic gated mechanism of action"

Mechanism of action describes how a drug, therapy, or medical product produces its effect in the body—the specific steps, targets, and biological processes it engages, like a key fitting into a lock to open a door. Investors care because a clear, well-understood mechanism reduces scientific uncertainty, supports regulatory approval and market confidence, and helps predict safety, effectiveness and additional uses, all of which influence a product’s commercial potential and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California.

The presentations will include data from the ongoing Phase I clinical trial of SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR NK cell therapy designed to selectively target CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in adults with relapsed/refractory acute myeloid leukemia (AML).

The presentations details are as follows:

Clinical Data Presentation
Rochelle Emery, MD, Medical Director at Senti Bio, will present:
“Promising Phase I Clinical Trial Results from SENTI-202-101, a First-in-Class, CD33 and/or FLT3 & not EMCN, Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Adults with R/R AML”

The presentation will highlight clinical data from the ongoing study evaluating the safety and preliminary anti-leukemic activity of SENTI-202.

Translational and Correlative Data Presentation
Enping Hong, PhD, Associate Director of Preclinical and Translational Science, will present:
“Promising Phase I Correlative SENTI-202 Data is Consistent with Clinical Activity & Unique Logic Gated Mechanism of Action”

The presentation will provide correlative analyses supporting observed clinical activity and the therapy’s logic-gated mechanism of action.

Workshop Participation
Brian Garrison, PhD, Vice President of Research and Translational Science, will lead a workshop titled:
“Harnessing Biomarker Discovery & Translational Tools to Accelerate NK Therapy Clinical Success”

The workshop will focus on strategies to advance NK cell therapy development through biomarker discovery and translational approaches.

About Senti Bio

Senti Bio is a clinical stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

What SENTI-202 data will Senti Biosciences (SNTI) present at the Innate Killer Conference on March 24–25, 2026?

Senti Biosciences will present Phase I clinical safety and preliminary anti-leukemic activity data for SENTI-202. According to Senti Biosciences, the presentation highlights ongoing trial results evaluating safety and early signals of clinical activity in relapsed/refractory AML patients.

Who is presenting SENTI-202 translational and correlative data for SNTI at the March 24–25, 2026 conference?

Enping Hong, PhD, will present translational and correlative SENTI-202 data supporting the therapy's mechanism. According to Senti Biosciences, the talk will describe correlative analyses consistent with observed clinical activity and the logic-gated mechanism of action.

What is the mechanism and target profile of SENTI-202 described by Senti Biosciences (SNTI)?

SENTI-202 is an off-the-shelf, logic-gated CAR NK therapy targeting CD33 and/or FLT3 while sparing EMCN-expressing healthy cells. According to Senti Biosciences, the design aims to selectively attack AML cells and reduce damage to EMCN-positive healthy tissues.

What will the Senti Biosciences (SNTI) workshop on March 24–25, 2026 cover regarding NK therapy development?

The workshop will focus on biomarker discovery and translational tools to advance NK therapy clinical success. According to Senti Biosciences, it will cover strategies to accelerate NK therapy development through biomarker-driven approaches and translational science.

Does the SENTI-202 presentation for SNTI include patient population details and trial phase?

Yes, the presentation covers the ongoing Phase I trial in adults with relapsed/refractory acute myeloid leukemia (AML). According to Senti Biosciences, the data reflect safety assessments and preliminary anti-leukemic activity in this R/R AML population.

When and where will Senti Biosciences (SNTI) present SENTI-202 data at the 11th Annual Innate Killer Conference?

Senti Biosciences will present SENTI-202 data at the Innate Killer Conference on March 24–25, 2026 in San Diego, California. According to Senti Biosciences, multiple sessions include clinical, translational, and workshop presentations by company scientists.